REG - Polarean Imaging PLC - University of Virginia Health Hospital agreement

Polarean ImagingAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250929:nRSc1086Ba&default-theme=true

RNS Number : 1086B  Polarean Imaging PLC  29 September 2025

29 September
2025

 

Polarean Imaging plc

("Polarean" or the "Company")

 

University of Virginia Health Hospital new supply agreement

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in functional Magnetic Resonance Imaging ("MRI") of the
lungs, announces that it has entered into a new supply agreement with the
University of Virginia Health ("UVA Health") to complete the implementation of
full clinical Xenon MRI capabilities.

 

UVA Health holds a unique place in medical imaging history as the site where
the first human patient was scanned using hyperpolarised Xenon MRI. The
institution upgraded its two research-grade hyperpolarisers to clinical-grade
systems in 2024 provided by Polarean, and UVA Health required some essential
additional equipment from Polarean to enable clinical Xenon MRI scans in their
clinical imaging area.

 

UVA Health is an integrated health system anchored by a world-class academic
medical center that includes a nationally recognised Comprehensive Cancer
Center and UVA Health Children's, the leading pediatric hospital in Virginia.
Its Hyperpolarized Xenon MRI Center faculty pioneered applications for a
variety of lung diseases, including asthma, cystic fibrosis, and
bronchopulmonary dysplasia. Their research programme was recently strengthened
by a $7.4 million US National Institutes of Health grant, awarded to evaluate
lung transplant rejection and abnormalities in the lungs of electronic
cigarette users using Xenon MRI, focusing on improving diagnosis and treatment
monitoring.

 

Professor Colin Derdeyn, MD, Interim Dean of the UVA School of Medicine and
previously Chair of the Department of Radiology and Medical Imaging at UVA
Health, said: "UVA Health has been a leader in Xenon MRI research for nearly
three decades, beginning with the world's first human lung scan using this
technology in 1996. Since then, our teams have made significant contributions
to its development and application across a range of pulmonary diseases.
Advancing to clinical implementation is a major step, not only for UVA Health,
but for the patients who will benefit from safer, more detailed evaluation of
lung disease. We are pleased to work with Polarean to bring this innovation
into routine care."

 

Christopher von Jako, PhD, CEO of Polarean, said: "We are delighted to support
UVA Health as they prepare to launch their first clinical Xenon MRI scan,
anticipated to occur later this year. Their deep and sustained commitment to
advancing pulmonary imaging - from early research breakthroughs to today's
clinical transition - perfectly aligns with Polarean's mission to provide
critical imaging solutions for chronic lung disease.

 

"UVA Health's decades-long leadership in Xenon MRI has been instrumental in
shaping the field, and we look forward to continuing our partnership to
improve lung health for patients everywhere."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018.

 

Enquiries:

 

 Polarean Imaging plc                                          www.polarean.com
                                                               (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean.com)
                                                               / www.polarean-ir.com
                                                               (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer                                           Via Walbrook PR

 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                                                                        +44 (0)20 7710 7600
 Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good

 Walbrook PR            Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Paul McManus / Marcus Ulker

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform.

 

For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

XENOVIEW® IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 6 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.

 

Please see full prescribing information at www.xenoview.net
(http://www.xenoview.net) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREANNPAFLSEFA